CUREator+ is a national program focused on accelerating the research translation and commercialisation of early-stage Australian medical research and medical innovations with commercial potential.
Selected by the Federal Government’s Medical Research Future Fund (MRFF) through a competitive process, Brandon BioCatalyst, managed by Brandon Capital, and ANDHealth will deliver CUREator+ through the $50 million 2021 MRFF BioMedTech Incubator (BMTI) program.
CUREator+ will provide small-to-medium enterprises (SMEs) with access to investment capital, commercial guidance, international expert networks, and hands-on support and mentorship to drive the translation and commercialisation of therapeutics (novel and repurposed), devices, diagnostics and digital technologies.
In addition to program oversight, SMEs will be supported to secure follow-on funding and facilitate their continued development to ultimately improve patient outcomes and generate jobs and income for the sector.
CUREator+ will run two funding rounds during the five-year program. The first funding round opened in August 2023 and the
eight successful startups were announced in December 2024. The second funding round opened in October 2024 and is now closed.
.svg)
.svg)
